IDXX vs PAHC vs COR Stock Comparison

Idexx Laboratories, Phibro Animal Health and Cencora Prices as of Oct 28, 2026 Peers: Industry group
COR Cencora, Inc.
$324.43 +6.8% 1M -3.3% 1Y
Market cap
$63.35B
P/E
24.1x
Revenue (TTM)
$332.77B
Div. yield
0.01%
Drug Distribution Healthcare
3 wins

Head to Head

12 decided of 12

Idexx Laboratories leads on 5 of the 12 questions below (Idexx Laboratories 5, Phibro Animal Health 4, Cencora 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionIDXXPAHCCORLeader
Larger companyMarket capitalisation $45.21B $1.58B $63.35B COR
Cheaper on earningsLower P/E, profitable companies only 39.7x 15.8x 24.1x PAHC
Cheaper on forward earningsLower price / next fiscal year consensus EPS 36.0x 11.1x 19.0x PAHC
Faster revenue growthRevenue growth, trailing twelve months +12.8% +17.1% +5.1% PAHC
More profitableNet margin, trailing twelve months 25.0% 6.6% 0.8% IDXX
Better return on capitalReturn on invested capital 45.6% 14.2% 14.4% IDXX
Less leveragedLower net debt / EBITDA 0.5x 2.1x 2.2x IDXX
Higher dividend yieldTrailing dividend yield 0.00% 0.01% 0.01% PAHC
Better 1-year returnPrice return, last 12 months -11.3% -9.1% -3.3% COR
Better 5-year returnAnnualised price return, 5 years -3.3%/yr +11.5%/yr +21.6%/yr COR
Less volatileAnnualised volatility, 1 year 32.0% 55.5% 32.7% IDXX
Higher overall scoreMean of the five percentile scores vs peers 78/100 68/100 53/100 IDXX

Percentile Scorecard

IDXXPAHCCOR

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisIDXXPAHCCOR
Valuation 75 #155 of 625 92 #52 of 625 63 #10 of 25
Growth 76 #147 of 602 85 #90 of 602 74 #7 of 24
Profitability 97 #18 of 549 85 #81 of 549 57 #11 of 24
Financial Health 46 #351 of 654 26 #485 of 654 24 #20 of 26
Shareholder Returns 93 #26 of 367 54 #171 of 367 47 #9 of 16
Overall 78 68 53
  • IDXX ranked among 672 companies in Pharmaceuticals and Biotechnology
  • PAHC ranked among 672 companies in Pharmaceuticals and Biotechnology
  • COR ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodIDXXPAHCCORSPY
1 month +6.4%+6.1%+6.8% +0.9%
3 months -1.2%+2.5%+1.8% +5.9%
6 months +1.7%-27.8%+4.2% +8.5%
Year to date -16.8%+1.4%-3.9% +13.3%
1 year -11.3%-9.1%-3.3% +12.4%
3 years +43.8%+251.7%+72.9% +88.1%
3 years, per year +12.9%+52.1%+20.0% +23.5%
5 years -15.5%+72.7%+165.9% +68.2%
5 years, per year -3.3%+11.5%+21.6% +11.0%
10 years +435.8%+45.4%+369.2% +263.4%
10 years, per year +18.3%+3.8%+16.7% +13.8%

Risk

MeasureIDXXPAHCCORSPY
Volatility, 1Y 32.0%55.5%32.7% 12.7%
Downside volatility, 1Y 31.2%59.8%39.5% 12.7%
Beta vs S&P 500, 1Y 0.800.75-0.15 1.00
Return / volatility, 1Y -0.35-0.16-0.10 0.98
Max drawdown, 5Y -51.3%-57.9%-32.6% -25.4%
From 52-week high -26.6%-36.4%-13.4% -0.9%
52-week high $766.68$59.58$374.75 $779.14
52-week low $504.70$28.52$252.74 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleIDXXPAHCCOR
P/E now vs peer median 39.0xmedian 17.4x 15.4xmedian 17.4x 23.9xmedian 23.9x
P/S now vs peer median 9.8xmedian 9.1x 1.0xmedian 9.1x 0.2xmedian 0.3x
EV/EBITDA now vs peer median 28.0xmedian 17.1x 8.1xmedian 17.1x 17.2xmedian 12.7x
P/FCF now vs peer median 35.4xmedian 19.0x 155.7xmedian 19.0x 15.2xmedian 15.4x
P/B now vs peer median 27.5xmedian 2.2x 4.0xmedian 2.2x 19.1xmedian 2.5x
PEG now vs peer median 2.58median 0.34 0.35median 0.34 1.34median 1.34

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsIDXXPAHCCOR
Revenue $4.55B $1.52B $332.77B
Gross profit $2.84B $512.52M $13.22B
Operating income $1.46B $194.40M $3.04B
Net income $1.14B $99.72M $2.65B
Free cash flow $1.25B $9.87M $4.06B
R&D $261.47M – –
EPS (diluted) $14.37 $2.43 $13.53
Cash & equivalents $196.93M $61.42M $2.82B
Total debt $968.86M $2.49B $11.72B
Shares (diluted) 79.31M 40.96M 193.94M
Enterprise value $44.42B $1.26B $52.25B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricIDXXPAHCCOR
P/E 39.0x 15.4x 23.9x
P/FCF 35.4x 155.7x 15.2x
P/Operating cash flow 32.4x 22.3x 12.8x
P/S 9.8x 1.0x 0.2x
P/B 27.5x 4.0x 19.1x
P/Tangible book 29.3x 4.3x -23.0x
EV/EBITDA 28.0x 8.1x 17.2x
EV/EBIT 31.0x 10.7x 23.3x
EV/Revenue 9.9x 1.4x 0.2x
EV/FCF 36.0x 209.9x 17.4x
EV/Operating cash flow 32.9x 30.0x 14.7x
PEG (3Y EPS CAGR) 2.58 0.35 1.34

Growth

14 metrics
MetricIDXXPAHCCOR
Revenue growth (1Y) 12.8% 17.1% 5.1%
Revenue CAGR (3Y) 9.0% 15.8% 9.4%
Gross profit growth (1Y) 14.4% 28.1% 20.0%
Gross profit CAGR (3Y) 10.5% 19.8% 15.0%
Operating income growth (1Y) 16.2% 76.0% 11.1%
Operating income CAGR (3Y) 11.7% 39.3% 9.5%
Net income growth (1Y) 15.6% 106.6% 38.9%
Net income CAGR (3Y) 12.9% 45.2% 16.2%
EPS growth (1Y) 18.1% 105.2% 39.3%
EPS CAGR (3Y) 15.1% 44.6% 17.9%
Operating cash flow growth (1Y) 51.4% -13.9% 176.7%
Operating cash flow CAGR (3Y) 22.5% 73.0% 14.1%
Free cash flow growth (1Y) 59.9% -76.4% 255.7%
Free cash flow CAGR (3Y) 28.4% 31.2% 13.3%

Profitability

14 metrics
MetricIDXXPAHCCOR
Gross margin 62.4% 33.8% 4.0%
EBITDA margin 35.4% 16.8% 1.2%
Operating margin 32.0% 12.8% 0.9%
Pretax margin 31.3% 9.0% 1.1%
Net margin 25.0% 6.6% 0.8%
FCF margin 27.5% 0.6% 1.2%
Operating cash flow margin 30.1% 4.5% 1.4%
Return on equity 71.9% 26.7% 77.4%
Return on assets 33.4% 6.8% 3.2%
Return on invested capital 45.6% 14.2% 14.4%
Return on capital employed 68.6% 16.8% 12.9%
Asset turnover 1.3x 1.0x 4.0x
Cash conversion (OCF / net income) 1.2x 0.7x 1.8x
Stock comp / revenue 1.4% 0.1% 0.0%

Financial Health

11 metrics
MetricIDXXPAHCCOR
Debt / assets 28.1% 41.1% 14.0%
Debt / equity 0.6x 1.6x 3.6x
Net debt / EBITDA 0.5x 2.1x 2.2x
Debt / FCF 0.8x 62.5x 2.9x
Liabilities / assets 53.2% 74.3% 96.1%
Equity / assets 46.8% 25.7% 3.9%
Interest coverage 38.6x 4.2x –
Current ratio 1.2x 3.0x 0.9x
Quick ratio 0.7x 1.1x 0.5x
Cash ratio 0.2x 0.3x 0.0x
Altman Z-score 20.21 3.09 4.65

Shareholder Returns

7 metrics
MetricIDXXPAHCCOR
Dividend yield – 1.3% 0.7%
Net buyback yield 2.4% – 1.6%
Shareholder yield 2.4% 1.3% 2.3%
Payout ratio (earnings) – 19.5% 17.7%
Payout ratio (FCF) – 197.3% 11.5%
Dividend growth (1Y) – 0.1% 8.7%
Dividend CAGR (3Y) – 0.0% 5.7%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusIDXXPAHCCOR
Forward P/E 36.0xFY2026 11.1xFY2027 19.0xFY2026
EPS, next fiscal year $15.63FY2026 $3.42FY2027 $17.08FY2026
EPS growth, next FY +19.5%FY2026 +6.2%FY2027 +6.7%FY2026
EPS growth, the year after +12.9% +9.6% +11.8%
Revenue, next fiscal year $5.00BFY2026 $1.53BFY2027 $328.56BFY2026
Revenue growth, next FY +16.3%FY2026 +0.6%FY2027 +2.2%FY2026
Revenue growth, the year after +0.6% -0.2% -0.3%
IDXX estimates →PAHC estimates →COR estimates →

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersIDXXPAHCCOR
Held by institutions 93.6% 51.5% 94.7%
Institutions holding 1,289 208 1,343
Change in shares held, QoQ +4.1% +3.1% +15.7%
Institutions buying 587 117 542
Institutions selling 496 73 610
Buyers to sellers 1.18 1.60 0.89
IDXX holders →PAHC holders →COR holders →

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

IDXXPAHCCOR
IDXX 1.00 0.31 0.12
PAHC 0.31 1.00 0.12
COR 0.12 0.12 1.00

Add a Peer

Largest companies in the same industry
IDXX · Animal Health
+MRKMerck +ZTSZoetis +ELANElanco Animal Health +CHWYChewy +NEOGNeogen +BFLYButterfly Network +ANIKAnika Therapeutics +ICCCImmucell
Plot all 33 Animal Health stocks → Plot all 37 Drug Distribution stocks →

Related Comparisons

IDXX vs MRKMerck IDXX vs ZTSZoetis IDXX vs ELANElanco Animal Health IDXX vs CHWYChewy

Frequently Asked Questions

Which is bigger, IDXX, PAHC and COR?

Cencora (COR) is the largest by market capitalisation: Idexx Laboratories (IDXX) $45.21B, Phibro Animal Health (PAHC) $1.58B, Cencora (COR) $63.35B.

Which stock is cheaper, IDXX, PAHC and COR?

Phibro Animal Health (PAHC) trades on the lowest price-to-earnings ratio (Idexx Laboratories (IDXX) 39.7x, Phibro Animal Health (PAHC) 15.8x, Cencora (COR) 24.1x). On next year's consensus earnings, Phibro Animal Health (PAHC) is cheapest (Idexx Laboratories (IDXX) 36.0x, Phibro Animal Health (PAHC) 11.1x, Cencora (COR) 19.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Phibro Animal Health (PAHC) grew revenue fastest over the trailing twelve months: Idexx Laboratories (IDXX) +12.8%, Phibro Animal Health (PAHC) +17.1%, Cencora (COR) +5.1%.

Which company is more profitable?

Idexx Laboratories (IDXX) has the highest net margin (Idexx Laboratories (IDXX) 25.0%, Phibro Animal Health (PAHC) 6.6%, Cencora (COR) 0.8%). On return on invested capital, Idexx Laboratories (IDXX) leads (Idexx Laboratories (IDXX) 45.6%, Phibro Animal Health (PAHC) 14.2%, Cencora (COR) 14.4%).

Which stock has performed better?

Over the past year Cencora (COR) returned the most: Idexx Laboratories (IDXX) -11.3%, Phibro Animal Health (PAHC) -9.1%, Cencora (COR) -3.3%. Over five years, Cencora (COR) compounded fastest (Idexx Laboratories (IDXX) -3.3%/yr, Phibro Animal Health (PAHC) +11.5%/yr, Cencora (COR) +21.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Phibro Animal Health (PAHC) has the highest dividend yield: Idexx Laboratories (IDXX) 0.00%, Phibro Animal Health (PAHC) 0.01%, Cencora (COR) 0.01%. Idexx Laboratories (IDXX) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Idexx Laboratories (IDXX) has been the steadiest (Idexx Laboratories (IDXX) 32.0%, Phibro Animal Health (PAHC) 55.5%, Cencora (COR) 32.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, IDXX, PAHC and COR?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Idexx Laboratories (IDXX) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.